OJBIPHY  Vol.7 No.3 , July 2017
Two Small Molecules, ZCL278 and AZA197 Show Promise in Influencing Protein Interactions Involving the Ras-Related Protein Cell division cycle 42 [Cdc42] to Modulate Its Oncogenic Potential
Abstract: Cdc42 is a member of the Rho subfamily of Ras-related proteins, which were among the first oncogenic proteins to be identified as playing a sig-nificant role in a variety of cellular events [Barbacaid, 1987, Ann. Rev. Biochem]. Equally important, Protein-Protein Interactions [PPIs] involving Cdc42 continue to highlight the role of Ras-related proteins’ relevance to cancer. As these proteins have been considered incapable of being “druggable”, due to a perceived lack of binding surface[s] that are amenable to small molecule targeting, there remains limited development of therapies to tackle diseased states caused by Cdc42-stimulated hyperactivity. Thusly, it has become important to characterize molecular details, including dynamics, of PPIs involving Cdc42 that may lend themselves as potential targets for therapeutic approaches. Recently, two small molecules, ZCL278 and AZA197, have shown promise in directly targeting Cdc42 to influence PPIs that are capable of causing Cdc42-stimulated abnormal signaling. In this editorial, we highlight recent studies that show case how these two small molecules may influence Cdc42-protein interactions.
Cite this paper: Muhoza, D. and Adams, P. (2017) Two Small Molecules, ZCL278 and AZA197 Show Promise in Influencing Protein Interactions Involving the Ras-Related Protein Cell division cycle 42 [Cdc42] to Modulate Its Oncogenic Potential. Open Journal of Biophysics, 7, 71-81. doi: 10.4236/ojbiphy.2017.73006.

[1]   Lin, Y. and Zheng, Y. (2015) Approaches of Targeting Rho GTPases in Cancer Drug Discovery. Expert Opinion on Drug Discovery, 10, 991-1010.

[2]   Smith, M.J., Neel, B.G. and Ikura, M. (2013) NMR-Based Functional Profiling of RASopathies and Oncogenic RAS Mutations. Proceedings of the National Academy of Sciences of the United States of America, 110, 4574-4579.

[3]   Johnson, C.W. and Mattos, C. (2013) The Allosteric Switch and Conformational States in Ras GTPase Affected By Small Molecules. Enzymes, 33, 41-67.

[4]   Bos, J.L. (1989) Ras Oncogenes in Human Cancer: A Review. Cancer Research, 49, 4682-4689.

[5]   Arias-Romero, L.E. and Chernoff, J. (2013) Targeting Cdc42 in Cancer. Expert Opin Ther Targets, 17, 1263-1273.

[6]   Mullard, A. (2012) Protein-Protein Interaction Inhibitors Get into the Groove. Nature Reviews Drug Discovery, 11, 173-175.

[7]   Spiegel, J., Cromm, P.M., Zimmermann, G., Grossmann, T.N. and Waldmann, H. (2014) Small-Molecule Modulation of Ras Signaling. Nature Chemical Biology, 10, 613-622.

[8]   Spoerner, M., Herrmann, C., Vetter, I.R., Kalbitzer, H.R. and Wittinghofer, A. (2001) Dynamic Properties of the Ras Switch I Region and Its Importance for Binding to Effectors. Proceedings of the National Academy of Sciences of the United States of America, 98, 4944-4949.

[9]   Spoerner, M., Hozsa, C., Poetzl, J.A., Reiss, K., Ganser, P., Geyer, M. and Kalbitzer, H.R. (2010) Conformational States of Human Rat Sarcoma [Ras] Protein Complexed with Its Natural Ligand GTP and Their Role for Effector Interaction and GTP Hydrolysis. The Journal of Biological Chemistry, 285, 39768-39778.

[10]   Morris, K.M., Henderson, R., Suresh Kumar, T.K., Heyes, C.D. and Adams, P.D. (2016) Intrinsic GTP Hydrolysis Is Observed for a Switch 1 Variant of Cdc42 in the Presence of a Specific GTPase Inhibitor. Small GTPases, 7, 1-11.

[11]   Chandrashekar, R., Salem, O., Krizova, H., McFeeters, R. and Adams, P.D. (2011) A Switch I Mutant of Cdc42 Exhibits Less Conformational Freedom. Biochemistry, 50, 6196-6207.

[12]   Friesland, A., Zhao, Y., Chen, Y.H., Wang, L., Zhou, H. and Lu, Q. (2013) Small Molecule Targeting Cdc42-Intersectin Interaction Disrupts Golgi Organization and Suppresses Cell Motility. Proceedings of the National Academy of Sciences of the United States of America, 110, 1261-1266.

[13]   Zins, K., Gunawardhana, S., Lucas, T., Abraham, D. and Aharinejad, S. (2013) Targeting Cdc42 with the Small Molecule Drug AZA197 Suppresses Primary Colon Cancer Growth and Prolongs Survival in a Preclinical Mouse Xenograft Model by Downregulation of PAK1 Activity. Journal of Translational Medicine, 11, 295.

[14]   Zins, K., Lucas, T., Reichl, P., Abraham, D. and Aharinejad, S.A (2013) Rac1/Cdc42 GTPase-Specific Small Molecule Inhibitor Suppresses Growth of Primary Human Prostate Cancer Xenografts and Prolongs Survival in Mice. PLoS One, 8, e74924.

[15]   Chandrashekar, R. and Adams, P.D. (2013) Prospective Development of Small Molecule Targets to Oncogenic Ras Proteins. Open Journal of Biophysics, 3, 207-211.

[16]   Feltham, J.L., Dotsch, V., Raza, S., Manor, D., Cerione, R.A., Sutcliffe, M.J., Wagner, G. and Oswald, R.E. (1997) Definition of the Switch Surface in the Solution Structure of Cdc42Hs. Biochemistry, 36, 8755-8766.

[17]   Prior, I.A., Lewis, P.D. and Mattos, C. (2012) A Comprehensive Survey of Ras Mutations in Cancer. Cancer Research, 72, 2457-2467.

[18]   Bourne, H.R., Sanders, D.A. and McCormick, F. (1990) The GTPase Superfamily: A Conserved Switch for Diverse Cell Functions. Nature, 348, 125-132.

[19]   Diaz, J.F., Escalona, M.M., Kuppens, S. and Engelborghs, Y. (2000) Role of the Switch II Region in the Conformational Transition of Activation of Ha-ras-p21. Protein Science, 9, 361-368.

[20]   Fidyk, N.J. and Cerione, R.A. (2002) Understanding the Catalytic Mechanism of GTPase-Activating Proteins: Demonstration of the Importance of Switch Domain Stabilization in the Stimulation of GTP Hydrolysis. Biochemistry, 41, 15644-15653.

[21]   Krengel, U., Schlichting, L., Scherer, A., Schumann, R., Frech, M., John, J., Kabsch, W., Pai, E. and Wittinghofer, A. (1990) Three-Dimensional Structures of H-Ras p21 Mutants: Molecular Basis for Their Inability to Function As Sifnal Switch Molecules. Cell, 62, 539-548.

[22]   Sutcliffe, M., Feltham, J., Cerione, R. and Oswald, R. (1994) Model Building Predicts an Additional Conformational Switch When GTP Binds to the Cdc42Hs Protein. Protein and Peptide Letters, 1, 84-91.

[23]   Barbacid, M. (1987) Ras Genes. Annual Review of Biochemistry, 56, 779-827.

[24]   Pai, E.F., Kabsch, W., Krengel, U., Holmes, K.C., John, J. and Wittinghofer, A. (1989) Structure of the Guanine Nucleotide Binding Domain of the Ha-Ras Oncogene Product p21 in the Triphosphate Conformation. Nature, 341, 209-214.

[25]   Pai, E.F., Krengel, U., Petsko, G.A., Goody, R.S., Kabsch, W. and Wittinghofer, A. (1990) Refined Crystal Structure of the Triphosphate Conformation of h-ras p21 at 1.35 Å Resolution: Implication for the Mechanism of GTP Hydrolysis. The EMBO Journal, 9, 2351-2359.

[26]   Rosnizeck, I.C., Graf, T., Spoerner, M., Trankle, J., Filchtinski, D., Herrmann, C., Gremer, L., Vetter, I.R., Wittinghofer, A., Konig, B. and Kalbitzer, H.R. (2010) Stabilizing a Weak Binding State for Effectors in the Human Ras Protein by Cyclen Complexes. Angewandte Chemie International Edition, 49, 3830-3833.

[27]   Gonzalez-Perez, V., Reiner, D.J., Alan, J.K., Mitchell, C., Edwards, L.J., Khazak, V., Der, C.J. and Cox, A.D. (2010) Genetic and Functional Characterization of Putative Ras/Raf Interaction Inhibitors in C. Elegans and Mammalian Cells. Journal of Molecular Signaling, 5, 2.

[28]   Kato-Stankiewicz, J., Hakimi, I., Zhi, G., Zhang, J., Serebriiskii, I., Guo, L., Edamatsu, H., Koide, H., Menon, S., Eckl, R., Sakamuri, S., Lu, Y., Chen, Q.Z., Agarwal, S., Baumbach, W.R., Golemis, E.A., Tamanoi, F. and Khazak, V. (2002) Inhibitors of Ras/Raf-1 Interaction Identified By Two-Hybrid Screening Revert Ras-Dependent Transformation Phenotypes in Human Cancer Cells. Proceedings of the National Academy of Sciences of the United States of America, 99, 14398-14403.

[29]   Arkin, M. (2005) Protein-Protein Interactions and Cancer: Small Molecules Going in for the Kill. Current Opinion in Chemical Biology, 9, 317-324.

[30]   Waldmann, H., Karaguni, I.M., Carpintero, M., Gourzoulidou, E., Herrmann, C., Brockmann, C., Oschkinat, H. and Muller, O. (2004) Sulindac-Derived Ras Pathway Inhibitors Target the Ras-Raf Interaction and Downstream Effectors in the Ras Pathway. Angewandte Chemie International Edition, 43, 454-458.

[31]   Wang, W., Fang, G. and Rudolph, J. (2012) Ras inhibition Via Direct Ras Binding—Is There a Path Forward? Bioorganic & Medicinal Chemistry Letters, 22, 5766-5776.

[32]   Scott, D.E., Ehebauer, M.T., Pukala, T., Marsh, M., Blundell, T.L., Venkitaraman, A.R., Abell, C. and Hyvonen, M. (2013) Using a Fragment-Based Approach to Target Protein-Protein Interactions. Chembiochem: A European Journal of Chemical Biology, 14, 332-342.

[33]   John, J., Rensland, H., Schlichting, I., Vetter, I., Borasio, G.D., Goody, R.S. and Wittinghofer, A. (1993) Kinetic and Structural Analysis of the Mg[2+]-Binding Site of the Guanine Nucleotide-Binding Protein p21H-ras. The Journal of Biological Chemistry, 268, 923-929.

[34]   John, J., Sohmen, R., Feuerstein, J., Linke, R., Wittinghofer, A. and Goody, R.S. (1990) Kinetics of Interaction of Nucleotides with Nucleotide-Free H-ras p21. Biochemistry, 29, 6058-6065.

[35]   Espina, C., Cespedes, M.V., Garcia-Cabezas, M.A., Gomez del Pulgar, M.T., Boluda, A., Oroz, L.G., Benitah, S.A., Cejas, P., Nistal, M., Mangues, R. and Lacal, J.C. (2008) A Critical Role for Rac1 in Tumor Progression of Human Colorectal Adenocarcinoma Cells. The American Journal of Pathology, 172, 156-166.

[36]   Gomez del Pulgar, T., Bandres, E., Espina, C., Valdes-Mora, F., Perez-Palacios, R., Garcia-Amigot, F., Garcia-Foncillas, J. and Lacal, J.C. (2007) Differential Expression of Rac1 Identifies Its Target Genes and Its Contribution to Progression of Colorectal Cancer. The International Journal of Biochemistry & Cell Biology, 39, 2289-2302.

[37]   Rossman, K.L., Worthylake, D.K., Snyder, J.T., Siderovski, D.P., Campbell, S.L. and Sondek, J. (2002) A Crystallographic View of Interactions between Dbs and Cdc42: PH Domain-Assisted Guanine Nucleotide Exchange. The EMBO Journal, 21, 1315-1326.

[38]   Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S.A., Triola, G., Wittinghofer, A., Bastiaens, P.I. and Waldmann, H. (2013) Small Molecule Inhibition of the KRAS-PDEdelta Interaction Impairs Oncogenic KRAS Signalling. Nature, 497, 638-642.